Torrent Pharmaceuticals Ltd , the flagship company of Torrent Group reported a 30.5 per cent year-on-year rise in net profit that stood at ₹591 crore for the second quarter of the financial year 2025-26.

During the quarter, the revenues of the company that operates in a single segment i.e. generic formulation business rose 14 per cent to ₹3,302 crore. The revenues from India at ₹1,820 crores were up by 12 per cent led by outperformance in focus therapies, while revenues from Brazil at ₹318 crores, were up by 21 per cent.

US business revenues at ₹337 crores, were up by 26 per cent, while Germany revenues at ₹303 crores, were up by 5 per cent.

In Germany, the growth was impacted due to supply disruption at a third party supplier. During the quarter, the R&D expenditure rose by 8 per cent

See Full Page